I
Ira Pastan
Researcher at Laboratory of Molecular Biology
Publications - 1304
Citations - 113191
Ira Pastan is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 160, co-authored 1286 publications receiving 110069 citations. Previous affiliations of Ira Pastan include Heidelberg University & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
DNase I sensitivity of the α2(I) collagen gene: correlation with its expression but not with its methylation pattern
TL;DR: The mechanism responsible for the large decrease in alpha 2(I) collagen gene expression in RSV transformed cells is different from the mechanism that isresponsible for the presence of a DNase I hypersensitive site in the promoter.
Journal ArticleDOI
Binding and internalization of α2-macroglobulin by cultured fibroblasts: Effects of monovalent ionophores
TL;DR: The data suggest that a proton gradient may be necessary for receptor-mediated endocytosis of α2M and some other ligands.
Journal ArticleDOI
Generation of high titer antisera in rabbits by DNA immunization.
TL;DR: Simple intradermal DNA immunization of rabbits can result in high titers of antibodies that can be used for a variety of purposes, and observations indicate that simple intrusion into rabbits of plasmid DNA encoding full length mesothelin can resultInfection of rabbits with GPI-linked, membrane-associated differentiation antigen produces antisera with titers as high as 1:100,000.
Journal ArticleDOI
Reduced mRNA levels for the multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines.
Khew-Voon Chin,Shyam S. Chauhan,Irene Abraham,Kathleen E. Sampson,Arkadiusz J. Krolczyk,Margaret Wong,Bernard P. Schimmer,Ira Pastan,Michael M. Gottesman +8 more
TL;DR: The sensitivity of the kinase defective CHO cell lines to multiple drugs results from decreased RNA levels for the multidrug‐resistance gene, and wild‐type Y1 cells are more drug sensitive despite having higher levels of P‐glycoprotein than the mutant cells.
Journal ArticleDOI
Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells.
Daniel Steinbach,Masanori Onda,Astrid Voigt,Kristin Dawczynski,Susan Wittig,Raffit Hassan,B. Gruhn,Ira Pastan +7 more
TL;DR: SS1(dsFv)PE38 is a recombinant anti‐mesothelin immunotoxin which is undergoing clinical evaluation in patients with mesothelin‐expressing tumors.